A Contrarian Case for Bayer: Legal Progress Sparks Analyst Upgrades Amid Cash Strain

Major banks raise Bayer price targets citing progress on glyphosate litigation and strong clinical data for drugs Kerendia and Nubeqa, despite near-term cash flow pressures.

Despite facing a period of significant financial pressure through 2026, the Leverkusen-based pharmaceutical and agricultural giant Bayer is attracting renewed optimism from major financial institutions. A series of recent analyst upgrades point to tangible progress in resolving legal uncertainties and promising clinical data, creating a notable divergence between the stock's current price and revised target valuations.

Operational Advances and Legal Milestones Drive Reassessment

The shifting sentiment is underscored by concrete actions from leading analysts:

• Oddo BHF raised its price target to €55.00 from €39.80.
• Goldman Sachs established a new target of €54.00.
• UBS upgraded the stock to "Buy," citing a €52.00 target.
• Barclays reaffirmed its "Overweight" rating with a €48.00 target.

This wave of positive revisions is primarily fueled by developments in the long-running glyphosate litigation. A pivotal $7.25 billion U.S. settlement received preliminary court approval in early March. Attention now turns to April 27th, when the U.S. Supreme Court is scheduled to hear the case of Monsanto v. Durnell. A favorable ruling by the end of June could potentially invalidate a substantial portion of the approximately 65,000 remaining claims.

Complementing the improved legal outlook are advancements in Bayer's drug pipeline. The kidney disease treatment Kerendia, following successful Phase III data in non-diabetic patients, now addresses a significantly expanded market. Analysts project annual sales potential reaching $2.6 billion for this asset. Concurrently, the cancer drug Nubeqa is reporting noticeable growth.

The Substantial Cost of Legacy Issues

However, managing these legal settlements comes with a steep short-term financial cost. Due to planned payouts of approximately €5 billion, company leadership anticipates a negative free cash flow of up to €-2.5 billion for the current year. To manage these obligations alongside an existing net debt of nearly €30 billion, the conglomerate will need to utilize an $8 billion credit facility. Consequently, the dividend will remain at a symbolic €0.11 per share to avoid impeding the crucial need for debt reduction.

A clear gap has emerged between the new analyst targets and the market's current valuation. Shares closed Friday at €37.65, trading notably below the 50-day moving average of €42.80. With a reading of 20.1, the Relative Strength Index (RSI) indicates a deeply oversold condition. The market awaits fresh fundamental catalysts on April 24th, when the company presents its final 2025 annual figures and holds a vote on the planned supervisory board restructuring at its virtual annual general meeting.